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Prion diseases, also called transmissible spongiform encephalopathies (TSEs),
lead to neurological dysfunction in animals and are fatal. Infectious prion
proteins are causative agents of many mammalian TSEs, including scrapie (in
sheep), chronic wasting disease (in deer and elk), bovine spongiform encepha-
lopathy (BSE; in cattle), and CreutzfeldteJakob disease (CJD; in humans). BSE,
better known as mad cow disease, is among the many recently discovered
zoonotic diseases. BSE cases were first reported in the United Kingdom in 1986.
Variant CJD (vCJD) is a disease that was first detected in 1996, which affects
humans and is linked to the BSE epidemic in cattle. vCJD is presumed to be
caused by consumption of contaminated meat and other food products derived
from affected cattle. The BSE epidemic peaked in 1992 and decreased there-
after; this decline is continuing sharply owing to intensive surveillance and
screening programs in the Western world. However, there are still new
outbreaks and/or progression of prion diseases, including atypical BSE, and
iatrogenic CJD and vCJD via organ transplantation and blood transfusion. This
paper summarizes studies on prions, particularly on prion molecular mecha-
nisms, BSE, vCJD, and diagnostic procedures. Risk perception and communica-
tion policies of the European Union for the prevention of prion diseases are also
addressed to provide recommendations for appropriate government policies in
Korea.1. Introduction
Transmissible spongiform encephalopathy (TSE) is
a general term for misfolded proteins, also called prions-
related diseases, which had been discussed only amongted under the terms of the C
0) which permits unrestrict
roperly cited.
ase Control and Preventiona few scientists until bovine spongiform encephalopathy
(BSE), better known to the public as mad cow disease,
became a public concern. It became widely known in the
1980s due to a sudden increase in the incidence of BSE
in Europe; in the 1990s, it drew people’s attention asreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
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known as mad cow disease for humans [1].
BSE caused by pathogenic prions is an emerging
zoonotic disease that can induce vCJD in humans.
Considering that the prevalence of BSE in the United
Kingdom (UK) has much to do with sheep farming,
this new cross-species epidemic appears to be related
to the current conditions involving frequent human
contact with animals, enlarged livestock markets,
increasing interchange/trade, and global warming
[2,3]. The first case of BSE was reported in the mid-
1980s, starting with 16 cattle; it has since increased
dramatically to about 190,000 cases worldwide [4e6],
concentrated in Europe. Thus, European countries are
taking precautionary measures against the disease, and
the prevalence of BSE has been decreasing since the
mid-1990s [7].
However, many problems remain from both social
and preventive medical perspectives since TSEs can
spread through food and blood transfusions with very
low concentrations of pathogenic prions, which current
technologies cannot detect. In addition, since they have
long incubation periods similar to other degenerative
chronic diseases, more scientific investigations must be
performed to identify the overall pathogeneses of BSE
and vCJD, and to develop treatment strategies for
them. Although the uncertainty surrounding prion
diseases must still be clarified, they are controllable
through intensive precautionary actions, as there are
many existing studies on prions and their basic
pathogenesis.
Reviews of prion diseases are already available
elsewhere [8e11]; thus, this paper will give an overview
of prion studies including not only prion diseases and
diagnostic methods, but also the perception and
communication of risk in the European Union (EU),
which has successfully established their policy against
BSE and vCJD as zoonotic diseases. This is for
providing recommendations to governments for devel-
oping appropriate policies, based on scientific policy to
free BSE.
1.1. Causes and prevalence of prion diseases
Prions, which were first proposed by Dr Prusiner at
the University of California, San Francisco, became
a hot topic since they do not have genes, unlike bacteria
or viruses, and are able to replicate, unlike toxic
elements [4]. Eventually, he scientifically answered
a number of questions and suggested that these gene-less
proteins can replicate in the body, induce the disease,
and be subsequently transmitted to other animals; he
received a Nobel Prize for his work in 1997. This type of
prion-only hypothesis is recognized as a new pathogenic
mechanism of neurodegenerative disorders [12].
The word “prion”, distinguished from virus or virion,
was coined by Prusiner to refer to the scrapie pathogen
in sheep; prion means a proteinaceous infectious particle[13]. PrPSc, a scrapie form of a prion known to be
pathogenic and misfolded, does not always induce
clinical symptoms; therefore, the PrPSc that induces
clinical symptoms is marked as a disease prion: PrPd.
However, prions already exist in animals and humans in
the cellular form of the protein (PrPC), which does not
have any pathogenic properties. The primary amino acid
sequences and the state of modification in both isoforms
of PrPSc and PrPC are identical; however, they have
different three-dimensional structures, which give them
distinct biochemical and biophysical properties. Also,
alterations in amino acid sequences change the confor-
mation of these proteins, resulting in a thermodynami-
cally stable protein variant (PrPSc) that can cause
diseases in both animals and humans [14].
When PrPC comes in contact with PrPSc, PrPC
changes into a thermodynamically stable PrPSc via
protein folding; then, PrPSc converts PrPC into another
PrPSc. After this process is repeated over time, PrPSc
accumulates in the body and results in induction of TSE
[15]. Although it is not certain whether TSEs are caused
by PrPSc alone or by a complex reaction with PrPSc and
other factors, such as other proteins, nucleic acids, or
pathogens [16], it is certain that the main causative agent
is PrPSc. However, to explain the replication of PrPSc
within the body, two thermodynamically stable PrPSc
molecules must be separated and combined with other
PrPCs. The animal’s genetic type and other additional
factors should be considered in the process [17].
Therefore, scientists assume that the hypothetical mac-
romoleculeddesignated protein Xdmay play a role in
the conversion from PrPC to PrPSc and continue to
search for candidates. At present, dozens of proteins in
the cytosol, plasma membrane, extracellular matrix, and
lipid rafts are known to interact with PrPC and/or PrPSc;
however, strong evidence for the identity of protein X
has not been revealed yet [18]. Identifying the existence
and role of protein X, prion diseases can be prevented
and/or treated. Normal PrPC, which is encoded on the
gene locus PRNP in the genome of hosts, is a glyco-
protein found in neuron cell membranes in animals and
humans. PrPC has a w40% a-helical and w3% b-sheet
conformation, whereas PrPSc has aw30% a-helical and
w40% b-sheet conformation. The conformational tran-
sition from the helices and hydrophobic regions of PrPC
is a major cause of the increase of b-sheet composition
in PrPSc (Figure 1) [19,20]. Since the conformational
alteration from PrPC to PrPSc is not immunogenic, the
immune system of the organism can hardly distinguish
the normal protein structure from the infectious prion
structure, except with respect to its stability [21]. Unlike
bacteria or viruses, pathogenic PrPSc cannot be removed
by regular alcohol or formalin sterilization processes,
and cannot be decomposed by proteolytic enzymes.
Moreover, it is resistant to heat, ultraviolet rays, and
chemicals. Under three times the atmospheric pressure
the materials for prion should be sterilized for more than
Figure 1. Normal and disease-causing prions structures [20].
Prion diseases 5918 minutes at 134e138C; surfaces should be sterilized
for over an hour with 2% sodium hypochlorite and 2N
sodium hydroxide at 20C, and equipment should be
sterilized for more than 12 hours with the same solution.
In laboratories, materials should be disinfected for more
than 4.5 hours at 132C or for 1 hour at 134e138C by
steam sterilization under pressure. Because it responds
well to alkaline conditions, highly concentrated sodium
hydroxide or phenol is used to decontaminate PrPSc
[22].
1.2. Specific risk material and the species
barrier
PrPSc in infected animals is concentrated in specific
areas. These areas are called specific risk material
(SRM) and include the brain, eyes, spinal cord, skull,
vertebral column, tonsils, and distal ileum; these are the
most crucial areas for disease management and control.
The disease is transmittable via surgical tools that came
into contact with SRM and via blood transfusion. Since
blood rarely contains the prion, it was considered safe
until a death caused by vCJD from a blood transfusion
was reported in the UK, which was alarming to the
public. From this case, the UK spent more than £200
million on a preventive process to protect surgical tools
against prion transmission. This shows that the occur-
rence of BSE or vCJD can cause an enormous amount
of indirect expenses, although they do not occur
frequently.
The species barrier makes it difficult for infectious
diseases to be transmitted from one species to another.
The value of the species barrier for prion disease
transmission between humans and cattle has been esti-
mated to be 4000, based on the study of BSE zoonosis.
However, a precautionary principle assumes that there is
only one value of species barrier between humans and
cattle, and suggests that the same dose that causes the
disease in cattle may affect humans in the same way
[23]. The experimental disease-inducing amount of
SRM in a single administration is 0.001 g injected
orally; 10 g can lead to BSE in all administered cattle[24]. The amount required to induce the disease is very
small; a scientific report submitted to the British Council
in 2001 states that an amount as small as one speck of
pepper may cause the disease [25]. Five grams of an oral
inoculum with brain homogenate from a BSE-infected
cattle in a primate (Cynomolgus macaques) resulted in
the development of a vCJD-like neurological disease 60
months after exposure [26].
Since such a small dose can cause the disease
affecting both humans and animals and there is currently
no cure, experiments on the PrPSc agent transmissible to
humans are supposed to be performed in Biosafety
Level 3 in the same manner as biologically strong
infectious agents (e.g., anthrax bacterium, Severe acute
respiratory syndrome, and the West Nile virus). It is
notable that in the study of pathogenic prions, the
protein particles have been observed to have many
different strains, which are under investigation [27]. In
fact, the discovery of new strains is related to the species
barrier and has many implications in disease control in
relation to the adaptation and progression of TSE [28].
In that respect, the EU, which has conducted much
research on BSE and vCJD, defines any beef that has
had contact with any SRM as SRM itself and advises
people not to use any cosmetic or food items with SRM,
although transmission via cosmetics or food has not
been reported yet. In BSE-infected cattle, PrPSc is also
found on peripheral nerves. Consequently, the whole
body of the infected cattle is disposed of according to
the EU regulation [29].
It is noteworthy that Payer’s patch tissue, which is the
most essential factor for PrPSc absorption, is mostly on
the ileum in humans; however, similar tissues are
predominantly found in the whole intestine including
mesentery in cattle [30]. Therefore, the EU defines the
whole intestine as SRM, the evidence of which is veri-
fied annually [31]. Recently, Switzerland submitted
a request (EFSA-Q-2009-00226) to the European Food
Safety Authority (EFSA) to reassess the use of bovine
intestines for stuffing sausage. The request was declined,
which demonstrates a careful approach to the
consumption of bovine intestine by global organizations.
Similarly, Koreans also need to take precautionary
action in consuming bovine intestines.2. Types of Prion Diseases
2.1. Scrapie
In 1732, scrapieda disease among sheepdwas first
reported in the UK, affecting the wool industry. The
official name for the disease (scrapie) was used from
1853 onward. The name scrapie is derived from one of
the clinical signs of the condition, wherein the affected
flock will compulsively scrape off their fleece against
rocks, trees, or fences. The disease apparently causes an
itching sensation in the animals. Other clinical signs
60 J. Lee, et alinclude excessive lip smacking, altered gaits, and
convulsive collapse [32]. Fortunately, other livestock
did not have such symptoms; therefore, it was only
a concern among sheep-farming communities, and not
among other people or other animal farmers.
In the 1900s, farmers in the UK started to feed cows
with internal organs or bones of sheep to benefit
economically from the increase in milk and meat
production. By the 1930s, other European countries and
the United States (USA) had adopted this practice.
Based on the findings of epidemiological studies on the
origin of BSE, this later became the main cause of prion
disease transmission from sheep to cows across the
species barrier [33].
As the PrPSc-inducing disease in sheep and cows is
also found in other animals, TSE can be considered an
inclusive term for the disease. TSE is subdivided into
BSE for bovines, vCJD for humans, scrapie for sheep,
chronic wasting disease (CWD) for deer, and trans-
missible mink encephalopathy for mink (Table 1); TSE
is found in 26 species, including goats, cats, and wild
ruminants [1,34,35]. It is noteworthy that prion diseases
among sheep and deer can be transmitted horizontally
by saliva, unlike BSE or vCJD [36]; CWD can even be
transmitted via aerosols, according to a recent animal
experiment report [37].
2.2. Bovine spongiform encephalopathy
There are several theories regarding the cause of the
first reported case of BSE in the mid-1980s; some insist
that the BSE pathogen (PrPSc) formed naturally and
others claim that the disease was caused by the cow feed
made from sheep infected with scrapie. By an extensive
epidemiologic investigation, the main cause for BSE
turned out to be a meat and bone meal (MBM) made
from the discarded bones and intestines of slaughtered
cows and sheep. In the UK, in particular, cow intestines
have been used in MBM as a protein supplement since
1972, which accelerated the increase of the occurrence
of BSE [1,38].
BSE has occurred in European countries that import
MBM from the UK; according to statistics from the
World Organization for Animal Health (Office Interna-
tional des Epizooties; OIE), there have been 190,628Table 1. Transmissible spongiform encephalopathy in
humans and animals [15,25]
Disease name
Animal
species
Reported
year
Scrapie Sheep 1732
CreutzfeldteJakob disease Humans 1920
Transmissible mink encephalopathy Mink 1947
Chronic wasting disease Deer 1967
Bovine spongiform encephalopathy Cows 1986
Feline spongiform encephalopathy Cats 1990
Variant CreutzfeldteJakob disease Humans 1996BSE cases in 25 countries worldwide as of August 30,
2012 (http://www.oie.int). Most reported cases are from
the UK, peaking in 1992, and in other countries the
epidemic peaked in 2002 or 2003; from then the number
started to decrease sharply.
BSE is a chronic degenerative neurological disease in
cows; part of the brain becomes sponge like, and
exhibits many different kinds of neurotic symptoms and
paralysis, eventually leading to death [39]. In BSE,
nerve cells and central nerve tissues take on a sponge-
like form. After approximately 2e5 years of incuba-
tion, the animal dies within approximately 2 weeks to 6
months of development of the disease. Clinical symp-
toms include extreme sensitivity to external stimuli such
as light and sound, neurotic changes (depression and
nervousness), positional imbalance, inability to stand
straight or move, paralysis in the hind legs, and paralysis
of the whole body before death [40].
At present, BSE is under surveillance by the OIE; in
Korea, it is classified as a second category of animal
epidemics along with scrapie and CWD. BSE has no
effect on the cattle younger than 7 months old; by the
time cows reach 24 months of age, there are many
variant prions in the body. Most occurrences of BSE are
in cows older than 36 months. Therefore, the OIE
examines the occurrence of BSE in 24-month-old cows.
In the UK, more than 184,000 cases of BSE have
been reported and more than 3 million cows were
destroyed to stop the spread of the disease; hence, the
UK strictly banned MBM. Owing to their efforts, the
occurrence of BSE was dramatically reduced. However,
since the 2000s, the disease has been spreading world-
wide, including in the USA, Japan, Israel, and various
African countries. Determining the precise number of
occurrences is challenging, as some infected animals do
not exhibit any particular symptoms. Without total
inspection and surveillance, it is difficult to research the
actual status of the disease [41].
Therefore, the EU places much emphasis on active
monitoring and surveillance systems, such as total
inspection, thorough removal of SRM (where 99% of
the pathogenic prions exist), banning MBM, and moni-
toring animal feed. Through such actions, BSE has
become manageable, but it is still not eradicated. The
USA also started to emphasize the development of an
effective animal-monitoring system over concerns for
human health [42].
However, some BSE cases have been reported even
after stricter surveillance was put in place, which means
that the disease is not controllable by monitoring animal
feed alone. Some scientific evidence is given regarding
this: pathogenic prions from the feces of TSE-infected
animal can be absorbed into the soil [43,44], can
combine with minerals in the soil, and can become
stable [45]. Although BSE does not seem to be trans-
mitted horizontally within species, such findings suggest
that more precautionary actions and approaches should
Table 2. Various types of CreutzfeldteJakob disease [50]
Type of
disease Cause
Sporadic
CJD
Sporadic. The cause is not known; it is
not common but is found worldwide
and is generally found in old people;
one in 1 million spontaneous
conversion
Familial
CJD
Genetic. It is caused by mutation of a
prion gene; 5e10% of all cases of
TSE. It is also called genetic CJD
Iatrogenic
CJD
Acquired. It is transmitted through
medical procedures including surgery,
transplantation, and blood transfusion
Variant
CJD
Acquired. It was discovered in 1996; it is
assumed that it is acquired by the
consumption of pathogenic prions
from BSE-infected beef (it was
initially called new variant CJD)
BSEZ bovine spongiform encephalopathy; CJDZ CreutzfeldteJakob
disease.
Prion diseases 61be performed in epidemiologic investigations, including
studying the possibility of transmission via a contami-
nated environment [46].
BSE-infected cows show the possibility of self-
mutation of the BSE prion, since the prion gene that
causes vCJD in humans, which had some mutations, was
found in the brains of affected cows. This implies that
a wide range of monitoring systems in DNA and/or
protein levels is necessary in addition to a strict animal
feed policy. Considering the transmission of BSE to
humans, control SRM is the most important step to take.
Based on recent findings on the relationship between
SRM and the occurrence of the disease, the EU devel-
oped some guidelines in April 2008 for its member
countries to follow regarding SRM. According to these
guidelines, the tonsils, whole intestine, and mesenterium
are all vulnerable to prions across all ages; the brains,
eyes, spinal cords, and skulls of cows that are older than
12 months are considered to be SRM.
Some older cows have an atypical form of BSE
(BASE), which differs from typical BSE with respect to
its molecular and biochemical properties; it appears to
be a sporadic BSE, although more precise etiological
studies need to be performed for confirmation. Recently,
attention has been given to BASE [47e49] because of
its infectivity and relation to vCJD.
2.3. Variant CJD
Clinical symptoms similar to those of CJD that were
reported in the 1920s were displayed in a patient who
consumed contaminated beef (affected with BSE); the
disease was called vCJD, which was first described in
1996. There are four types of CJDs: two nontransmit-
table CJDs, including sporadic CJD (sCJD) and familial
or genetic CJD (implying a genetic cause), and two
transmittable CJDs, including iatrogenic CJD and vCJD
(Table 2).
An endemic disease similar to CJD was found in
cannibal tribes (such as the Fore, Gimi, and Yate in
Papua New Guinea) who used to eat the dead bodies of
their relatives as part of their rituals. This endemic
disease, called kuru (meaning “shiver” in Uruna or
Guzigli, among other tribes), was first reported in 1957.
At that time, the cause could not be identified, so people
assumed that the disease was caused by an unknown
virus. However, ever since cannibalism was banned, the
incidence of kuru decreased sharply.
Meanwhile, many studies have sought to identify the
association between specific genotypes and the occur-
rence of the disease; a correlation between vCJD and
methionine homozygote (MM type) at codon 129 in the
human prion suggests that the MM type is highly related
and susceptible to prion infection [51], and is clearly
documented as a significant genetic risk factor [52]. A
study on kuru among cannibal tribes shows that the
incubation period of prion diseases differs among indi-
viduals based on genotype [53]. The MM type at codon129 of the prion is most common in Korean people and
has the shortest incubation period, with death following
shortly after disease development; the methionineeva-
line heterozygote (MV type) appears to be most resistant
to the disease, and a case with 40 years of incubation has
also been reported. At present, all vCJD patients in
Europe (including patients affected through transfusion
[54]) have the MM type except for one case [55].
Therefore, Aguzzi at University Hospital of Zurich in
Switzerland warns that patients should be observed for
at least 40 years since the number of patients with the
MV type may increase in the future. The Spongiform
Encephalopathy Advisory Committee appointed by
ministers from the UK assumes that there may be
4000e10000 infected persons with no symptoms in the
UK; however, valine homozygote- (VV type) or MV-
type patients may die of different causes due to the
long incubation period after they have been exposed to
the pathogenic prion.
Since vCJD was first reported in 1996, a total of 224
patients with this disease from 12 countries have been
identified worldwide, as shown in Table 3; the main
symptoms include unstable emotions; abnormal senses;
paralysis in linguistic, visual, and other senses; as well
as the inability to move and cognitive disability before
death [56,57]. While sCJD is common in older people,
vCJD can occur in young people after a short incubation
period [58]. There is much epidemiological and labo-
ratory evidence of a strong correlation between variants
of CJD and BSE; vCJD differs from other CJDs clini-
cally and histopathologically, and the initial extended
exposure of the population to potentially BSE-
contaminated food (1984e1986) was geographically
and chronologically consistent with the initial onset of
vCJD cases (1994e1996), considering the incubation
Table 3. Incidence of vCJD until August 2012
Country
Number of
primary cases
Number of secondary cases:
blood transfusion
Cumulative residence in the UK for >6 months
during 1980e1996
Canada 2 0 1
France 27 0 1
Italy 2 0 0
Japan 1 0 0
Netherland 3 0 0
Portugal 2 0 0
Republic of Ireland 4 0 2
Saudi Arabia 1 0 0
Spain 5 0 0
Taiwan 1 0 1
UK 173 3 176
USA 3 0 2
Total 224 3 183
VCD Z variant CreutzfeldteJakob disease.
62 J. Lee, et alperiod [1,59]. The facts that sCJD occurs in old people
at the ratio of one to two out of 1 million people and
vCJD is frequent in people in their 20s and 30s have led
the public to believe that the dietary habits of the
younger generation (who tend to eat more fast food such
as hamburgers) may be the cause of the disease.
However, recent findings suggest that age-related body
conditions are the causative factors of the disease [60].
The EU has been establishing countermeasures against
the transmission of vCJD via blood transfusion. Current
studies are focusing on the possibility of transmission
via dental treatment [61,62].3. Diagnostic Methods
At present, a reliable diagnosis of prion disease is
possible only through autopsy since there is no
approved method for detecting prion levels, which are
too low to be detected by any test, in the peripheral
nervous systems of live animals or humans. Thus,
tissues of the central nervous system, including the
brain and spinal cord, obtained at autopsy are used for
prion diagnostic tests using immunology-based tech-
niques such as enzyme-linked immunosorbent assay
(ELISA), immunohistochemistry, and immunoblotting;
a histopathological test is then performed forTable 4. Prion detection methods for the diagnosis of BSE [63
Method Specime
Rapid test using ELISA Fresh brain tissue
Histopathological test Formalin-fixed b
Immunohistochemistry Formalin-fixed b
Western blot Fresh brain tissue
Electron microscopy Fresh brain tissue
Bioassay Fresh tissue
BSE Z bovine spongiform encephalopathy; ELISA Z enzyme-linked immunconfirmation. However, the final confirmation is ob-
tained by performing a bioassay to assess the infectivity
of the pathogen; this is the most sensitive test and uses
a transgenic mouse with the human prion gene to detect
pathogenic PrPd by observing the infection. Moreover,
DNA sequencing for determination of genetic variations
is also considered.
The standard diagnosis procedures for BSE suggested
by the OIE include ELISA, Western blotting, and
immunohistochemical methods to test brain tissues
(Table 4). However, simple immunological tests to detect
BSE cannot distinguish PrPSc from PrPC. Therefore, the
target specimen should be processed by proteinase K
(PK) first, and then the remaining PK-resistant prions
such as PrPSc are detected. For rapid testing, 15 rapid
diagnosis kits are available; the tests most frequently
used around the world are shown in Table 5.
However, authorized tests that use antigeneantibody
reactions are good for highly concentrated specimens,
such as the brain and spinal cord, since the amount
detectable by ELISA-based procedures is so low that
they cannot be applied to actual blood specimens,
through which the disease can be transmitted. Therefore,
many scientific efforts have been made to overcome this
shortcoming, such as protein misfolding cyclic amplifi-
cation, which uses the replication of the conformation of
a protein [65], and real-time immuno-polymerase chain,64]
n Detection of
PrPSc antigen
rain tissue Spongiform in brain tissue
rain tissue PrPSc antigen
PrPSc antigen
Scrapie-associated fibril
PrPSc and infectivity
osorbent assay.
Table 5. Approved and most frequently used rapid tests for the detection of BSE [19,63,64]
Product name (company) Diagnostic method Authorized country Note
Prionics-Check
Western test
(Prionics AG)
Western blot using the
proteinasedprocessed specimen
using an antigen to prion
EU
USA
Specimen: 0.5 g obex tissue
Limit: w5.0e20 pmol
Test period: w6e8 h
Prionics-Check LIA
(Prionics AG)
Sandwich ELISA EU
USA
Specimen: 0.5 g obex tissue
Limit: w1.0e5.0 pmol
Test period: 4 h
Bio-Rad test (Bio-Rad) Sandwich ELISA EU
USA
Japan
Specimen: 0.35 g obex tissue
Limit: w0.5e2.0 pmol
Test period: 6 h
Enfer test (Abbott Labs) Simple ELISA EU
USA
Japan
Limit: w1e10 pmol
Test period: 4 h
CDI test
(Impro Biotechnology)
Immunity analysis based on
the structural differences
EU
USA
Japan
Limit: w0.5e5.0 pmol
Test period: 8 h
No proteinase K
Herd-check
(IDEXX Laboratories)
Immunity analysis after separating
the variant prion (PrPSc)
from brain tissue specimens
USA Test period: w4e5hours
No proteinase K
ELISA Z enzyme-linked immunosorbent assay.
Prion diseases 63reaction (PCR), which utilizes a combination of anti-
body features and the sensitivity of PCR. Recently, real-
time quaking-induced conversion has been developed
for an assay in which disease-associated prion protein
initiates a rapid conformational transition in recombi-
nant prion protein, resulting in the formation of amyloid
that can be monitored in real time [66]. Nevertheless,
although these new diagnostic methods have more than
100 times the sensitivity of the conventional ELISA
method, they still have unstable backgrounds or give
false positives, making it difficult to use them as
authorized tests.
However, diagnostic methods to determine patho-
genic PrPd based on PK resistance are limited, since PK-
sensitive prions with pathogenic characteristics have
been found [67]. Conventional tests for BSE or vCJD
cannot detect PK-sensitive prions. Furthermore, some
cases diagnosed as dementia may actually be cases of
vCJD [68]. Therefore, there is an urgent need to develop
novel diagnostic tests that are faster and more accurate
in detecting new types of prions [69].
3.1. Risk perception, communication, and
management of prion diseases
The occurrence of BSE or vCJD in any country is
beyond a simple outbreak of an incurable disease; it
affects the economy, society, and the meat market due to
changes in policies for exportation and importation. In
these situations, scientists should provide accurate
information to the public [70]. However, despite the
guidelines suggested by the OIE, the fact that Canada,
the USA, and the EU, which have had BSE outbreaks,
have different countermeasures and policies indicates
that science is not the only thing that needs to be
considered in risk management of BSE.Consumers’ trust in the government and industry can
affect the degree of how science should be reflected in
policy. Thus, when policies are re-established, scientific
findings should be clearly communicated among interest
groups through open discussion and public opinion in
advance. In this process, the risk perception of the
government and food industry should be treated and
considered equally as the overall risk perception of the
public. Therefore, policy makers must consider risk
communication to come up with strategies and plans.
Two of the conclusions and recommendations with
respect to the TSE roadmap from the workshop for the
EU countries on risk perception and communication
among interest groups are described below [29]. First,
SRM control and feed bans should be considered, by all
countries, as the most important policies for BSE risk
regulation; any relaxation of these policies should be
made with extreme caution, based on solid scientific
knowledge and accompanied by an effective commu-
nication strategy toward stakeholders as well as the
general public. Second, surveillance systems are also
important, although most countries consider testing
regimens merely as tools for epidemiological moni-
toring of the disease. In that respect, active surveillance
systems should be retained for some more time,
although the current regulatory design can be modified
to be more flexible when all stakeholders are in
a consensus.
The EU has separate organizations for evaluation and
management that aid in controlling BSE and vCJD and
public understanding, thus putting a fair and accurate
control system in place. Risk assessment is performed
by the EFSA, while risk management is carried out by
the Directorate General for Health and Consumer
Affairs. Two different organizations can achieve
64 J. Lee, et ala balance in a politically sensitive issue and prevent
each other from distorting the scientific truth, which is
a very desirable situation in controlling zoonotic
diseases such as BSE.
The communication channel for prevention of the
epidemic is important. Most of the misunderstandings
regarding BSE are due to the absence of or miscon-
ception about risk communication and risk management
[71] in societies. It is very risky to mention this disease
without considering the difference between laboratory
findings and field applications in quarantine, particularly
when establishing policies that are relevant to daily life
[72]. The EU maintains estimations of cow age through
a history tracking system called traceability, in which
the electronic ear tag of the cow must match its history
document before it can be slaughtered. Because of such
strict management, BSE outbreak is decreasing in the
EU. However, there are still some nonscientific opinions
based on the distorted understanding; some people
believe that it does not matter to assume a cow’s age by
examining its teeth while importing SRM and that this
disease itself is going to disappear soon.
The USA banned the import of human sperm for
in vitro fertilization from Northern Europe due to vCJD
risk. Although vCJD infection via sperm is not reported
yet, the USA took this strong action to protect its people
from Europe where prion diseases are more prevalent.
Among scientists, the possibility of the occurrence of
vCJD in the USA has been discussed continuously [73].
Such strict risk management implies how government
policy should reflect both public opinions and scientific
truth through careful communication, considering that
there was a meaningless probability controversy over
the transmission of disease via the importation of beef.
Furthermore, farming and slaughtering systems of
importing countries are lagging behind those of the
exporting countries such as the EU and the USA, so it is
reasonable to demand strict management and quarantine
to exporting countries. From the perspective of
preventive medicines, such opinions are very risky and
irresponsible. Poor farming and slaughtering conditions
in importing countries mean more favorable conditions
for the disease to spread even when there is only a small
threat to the nation. According to the EU’s geographical
BSE-risk analysis for the risk control of BSE, more
strict policies and actions should be taken to prevent
BSE from spreading to countries with poorer conditions
[74].4. Concluding Remarks
All emerging zoonotic diseases are not simple
diseases and involve sociocultural issues because of
their threatening and fearful characteristics. In that
respect, BSE and vCJD are typical emerging epidemics
along with AIDS; these diseases are still progressive andbeing studied. However, new information on the path-
ogenesis of these diseases is found every year; it is
hoped, on the basis of the experience in the EU, that
BSE and vCJD can be controlled, and their incidence be
lowered gradually. Nevertheless, for risk reduction,
strict precautionary principles should be applied since
prevention is the most effective way of controlling this
emerging disease that has not been experienced before.
Although OIE regulations are expected to be relaxed
in time to keep up with the free-trade era, managing
SRM is the most important aspect in controlling this
disease. In one case, it took 5 years to change the age
regulation of the EU on SRM (up to 6 months). The
different regulations of the OIE and the EU regarding
SRM standards cause confusion among people. SRM
standards set by the OIE are “conditions or guidelines
for trade” that can prevent the disease from spreading
from one country to another. Based on these criteria,
countries are supposed to establish their own trade
regulations in which their industry structures, conditions
for controlling the disease, and dietary habits should be
considered. In other words, OIE regulations are the
necessary conditions for all countries to follow to
prevent the spread of the disease. However, SRM stan-
dards set by the EU are “scientifically sufficient condi-
tions” that participating countries with different cultural
and industrial backgrounds can utilize [75].
In Korea, it is critical to implement a traceability
system or active total inspection to prevent prion diseases
as soon as possible. In fact, the possibility of BSE and
vCJD occurring naturally in Korea is extremely low. The
major reason for this is that there are not enough
preconditions for such diseases to occur. Korea has
historically had few sheep farms. A British national
institution reports that one of the main causes of the BSE
outbreak in the UK was feeding cows with sheep intes-
tines [25]. However, Korea has not developed sheep
farming, so the precondition of the BSE and vCJD
pandemic does not exist there. The second reason is that
Koreans used to consume cow intestines. For the
epidemic to spread, there should be at least some infected
entities; after the tipping point (threshold), it becomes an
epidemic [76,77]. Prion diseases have species barriers;
within one species, the diseases spread more easily and
quickly. However, a step for the multiplication of prions
within a species is blocked since Koreans consume cow
intestines themselves rather than feeding them to cows. In
that respect, it is almost impossible for BSE or vCJD to
occur naturally in Korea. If a BSE outbreak is reported in
Korea, the cause would likely be from outside the
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